Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma

Oncology Letters

Volumn 4, Issue 6, 2012, Pages 1321-1324

  Ma, Ruimin ^a   Zhang, Guojun ^a   Wang, Huimin ^b   Lv, Hong ^a   Fang, Fang ^a   Kang, Xixiong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INNER MONGOLIA PEOPLE S HOSPITAL   (China)

Author keywords

Glioma; Malignant transformation; miR 544

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ARTICLE; ASTROCYTOMA; BLOOD LEVEL; CANCER GRADING; CANCER GROWTH; DOWN REGULATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; PEARSON SYNDROME; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; TISSUE LEVEL;

EID: 84867280037     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.918     Document Type: Article

References (29)

1. Martinho O, Granja S, Jaraquemada T, et al: Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS One 7: e30769, 2012.
2. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
3. Malzkorn B, Wolter M, Liesenberg F, et al: Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20: 539-550, 2010.
4. Castellano L, Giamas G, Jacob J, et al: The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 106: 15732-15737, 2009.
5. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
6. Zhang Y, Dutta A and Abounader R: The role of microRNAs in glioma initiation and progression. Front Biosci 17: 700-712, 2012.
7. McDonald JS, Milosevic D, Reddi HV, Grebe SK and Algeciras-Schimnich A: Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57: 833-840, 2011.
8. Hu Z, Chen X, Zhao Y, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-1726, 2010.
9. Watanabe K, Sato K, Biernat W, et al: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523-530, 1997.
10. Jung TY, Jung S, Moon JH, Kim IY, Moon KS and Jang WY: Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg 113: 752-757, 2011.
11. Stupp R, Reni M, Gatta G, Mazza E and Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63: 72-80, 2007.
12. Weller M, Malipiero U, Aguzzi A, Reed JC and Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995.
13. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453, 2007.
14. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007.
15. Weber RG, Sabel M, Reifenberger J, et al: Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 13: 983-994, 1996.
16. Bigner SH, Matthews MR, Rasheed BK, et al: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155: 375-386, 1999.
17. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
18. Conti A, Aguennouz M, La Torre D, et al: miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 93: 325-332, 2009.
19. Shi L, Cheng Z, Zhang J, et al: hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236: 185-193, 2008.
20. Quintavalle C, Garofalo M, Zanca C, et al: miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 31: 858-868, 2012.
21. Lee ST, Chu K, Oh HJ, et al: Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 102: 19-24, 2011.
22. Rao SA, Santosh V and Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23: 1404-1417, 2010.
23. Thayanithy V, Sarver AL, Kartha RV, et al: Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone 50: 171-181, 2012.
24. Brase JC, Johannes M, Schlomm T, et al: Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128: 608-616, 2011.
25. Ng EK, Chong WW, Jin H, et al: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58: 1375-1381, 2009.
26. Yang CC, Hung PS, Wang PW, et al: miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med 40: 397-404, 2011.
27. Wulfken LM, Moritz R, Ohlmann C, et al: MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6: e25787, 2011.
28. Pigati L, Yaddanapudi SC, Iyengar R, et al: Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 5: e13515, 2010.
29. Zen K and Zhang CY: Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32: 326-348, 2012.